Tenaya Therapeutics (TNYA) Total Liabilities (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Total Liabilities of $28.9 million for Q1 2026, up 17.61% year-over-year from $24.6 million in Q1 2025, and up 22.09% quarter-over-quarter from $23.7 million in Q4 2025.
Tenaya Therapeutics (TNYA) Total Liabilities (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $28.9 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 17.61% year-over-year to $28.9 million; the TTM figure through Mar 2026 stood at $28.9 million (up 17.61% YoY), while the FY2025 annual figure was $23.7 million, down 12.66% from the prior year.
- Total Liabilities for Q1 2026 stood at $28.9 million, up from $23.7 million in the prior quarter.
- The five-year high for Total Liabilities was $35.6 million in Q4 2022, with the low at $22.1 million in Q3 2025.
- The 5-year median for Total Liabilities is $28.9 million (2026), against an average of $28.4 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities rose 29.83% in 2022, then decreased 23.52% in 2025.
- Tenaya Therapeutics' Total Liabilities stood at $35.6 million in 2022, then retreated by 12.59% to $31.1 million in 2023, then slipped by 12.88% to $27.1 million in 2024, then dropped by 12.66% to $23.7 million in 2025, then grew by 22.09% to $28.9 million in 2026.
- Business Quant data shows TNYA's Total Liabilities at $28.9 million in Q1 2026, $23.7 million in Q4 2025, and $22.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Tenaya Therapeutics | 150.58 Mn | 150.58 Mn | - | 24.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.13 Mn |
| Mar 31, 2026 | 28.88 Mn |
| Dec 31, 2025 | 23.66 Mn |
| Sep 30, 2025 | 22.11 Mn |
| Jun 30, 2025 | 22.32 Mn |
| Mar 31, 2025 | 24.56 Mn |
| Dec 31, 2024 | 27.09 Mn |
| Sep 30, 2024 | 27.98 Mn |
| Jun 30, 2024 | 29.19 Mn |
| Mar 31, 2024 | 26.72 Mn |
| Dec 31, 2023 | 31.09 Mn |
| Sep 30, 2023 | 28.51 Mn |
| Jun 30, 2023 | 30.81 Mn |
| Mar 31, 2023 | 29.93 Mn |
| Dec 31, 2022 | 35.57 Mn |
| Sep 30, 2022 | 29.98 Mn |
| Jun 30, 2022 | 32.06 Mn |
| Mar 31, 2022 | 32.40 Mn |
| Dec 31, 2021 | 35.66 Mn |
| Sep 30, 2021 | 28.10 Mn |